{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:31:53Z","timestamp":1777307513049,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["CSTB2022NSCQ-MSX0934"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX0934"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703057\/H1611"],"award-info":[{"award-number":["81703057\/H1611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.gendis.2025.101978","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:17:39Z","timestamp":1765441059000},"page":"101978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blockade of co-inhibitory receptor immune checkpoint protein TIM3\/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-7543","authenticated-orcid":false,"given":"Binglan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaorong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9149-3677","authenticated-orcid":false,"given":"Bingqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.gendis.2025.101978_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gendis.2025.101978_bib2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.gendis.2025.101978_bib3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2025.101978_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2015.11.003","article-title":"Reprogramming the tumor microenvironment to enhance adoptive cellular therapy","volume":"28","author":"Beavis","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.gendis.2025.101978_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-6-47","article-title":"Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges","volume":"6","author":"Han","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101978_bib7","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor T-cell efficacy in solid tumors","volume":"26","author":"Fuc\u00e0","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.gendis.2025.101978_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.gendis.2025.101978_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101978_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/sj.jid.5700616","article-title":"TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells","volume":"127","author":"Wiener","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101978_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2326-6066.CIR-14-0156","article-title":"The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas","volume":"3","author":"Komohara","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","article-title":"Tim-3 expression and its role in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053834","article-title":"Tim-3 expression in cervical cancer promotes tumor metastasis","volume":"8","author":"Cao","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.gendis.2025.101978_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101978_bib17","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.14169","article-title":"Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells","volume":"110","author":"Nakajima","year":"2019","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.gendis.2025.101978_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.gendis.2025.101978_bib19","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.gendis.2025.101978_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2025.101978_bib22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.gendis.2025.101978_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6647292","article-title":"Low distribution of TIM-3+ cytotoxic tumor-infiltrating lymphocytes predicts poor outcomes in gastrointestinal stromal tumors","volume":"2021","author":"Zhuang","year":"2021","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101978_bib24","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.gendis.2025.101978_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104112","article-title":"Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model","volume":"352","author":"Song","year":"2020","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101978_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gendis.2025.101978_bib28","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci Rep"},{"issue":"101","key":"10.1016\/j.gendis.2025.101978_bib29","doi-asserted-by":"crossref","first-page":"eadp7302","DOI":"10.1126\/sciimmunol.adp7302","article-title":"Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity","volume":"9","author":"Zhang","year":"2024","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1744921","article-title":"Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.gendis.2025.101978_bib31","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.gendis.2025.101978_bib32","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00262-020-02638-0","article-title":"TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of \u03b3\u03b4 T cells","volume":"69","author":"Guo","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.gendis.2025.101978_bib33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.101978_bib34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.gendis.2025.101978_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/intimm\/dxy006","article-title":"Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR\/Cas9 genome editing","volume":"30","author":"Ouchi","year":"2018","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.gendis.2025.101978_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.gendis.2025.101978_bib38","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.gendis.2025.101978_bib39","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gendis.2025.101978_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-011-0977-7","article-title":"In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells","volume":"60","author":"Yang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"27","key":"10.1016\/j.gendis.2025.101978_bib41","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in Primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Investig"},{"issue":"11","key":"10.1016\/j.gendis.2025.101978_bib43","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.4049\/jimmunol.1003870","article-title":"Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection","volume":"186","author":"Allie","year":"2011","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101978_bib44","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","article-title":"Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells","volume":"20","author":"Lee","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"Pt A","key":"10.1016\/j.gendis.2025.101978_bib45","article-title":"Dominant negative TGF\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer","volume":"124","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.gendis.2025.101978_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2021.06.007","article-title":"Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells","volume":"139","author":"Jafarzadeh","year":"2021","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101978_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:32:22Z","timestamp":1777303942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225004672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2352304225004672"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101978","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of co-inhibitory receptor immune checkpoint protein TIM3\/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101978"}}